[Apr 24, 2026] RAPS RAC-GS Exam Dumps Are Essential To Get Good Marks [Q58-Q78]

Posted On April 24, 2026

[Apr 24, 2026] RAPS RAC-GS Exam Dumps Are Essential To Get Good Marks

Latest RAPS RAC-GS Dumps with Test Engine and PDF (New Questions)

RAPS RAC-GS Certification Exam covers a wide range of topics that are essential for regulatory professionals. Some of the key topics that are covered in the exam include the regulatory requirements for drugs, medical devices, biologics, and other healthcare products. Additionally, the exam covers topics such as regulatory strategy, quality systems, and compliance. RAC-GS exam is designed to be challenging and comprehensive, and it requires a thorough understanding of the regulatory landscape in the healthcare industry.

NEW QUESTION 58
You discover that your company’s top selling product in the last two years has been used off-label. The
off-label use is estimated to be about 70%, and it has been consistent since the product was first released
to the market. Which of the following is MOST appropriate?

Discuss with regulatory authorities to investigate how to have the off-label indication approved.

No action is required since it is an off-label use.

Advise the senior management to send a “Dear Dr.” letter.

File a report to regulatory authorities and advise the marketing department to prevent future off-label
use.

NEW QUESTION 59
A company is developing a new medical device. During which initial stage is it MOST appropriate (or a
regulatory affairs professional to become involved?

Concept development and validation

Concept development and early technical design

Early technical design and product release

Product release and validation

NEW QUESTION 60
Which term does NOT describe the same concept as the others?

Biosimilars

Follow-on protein products

Monoclonal antibody

Subsequent entry biologics

NEW QUESTION 61
When applying for marketing approval of a drug for a rare disease, which requirement can be waived?

Pre-clinical studies

Phase I clinical trials

Phase I and II clinical trials

Phase III clinical trials

NEW QUESTION 62
A regulatory affairs professional has submitted a package for regulatory review. According to the
regulation, the regulatory authority will need to respond within 90 days of submission. If there is no
response after the deadline, what is the BEST approach?

Contact the regulatory authority, ask for clarification about the delay, and provide answers to any
outstanding questions.

Contact the regulatory authority, ask for clarification about the delay, and demand a decision be made
regarding the submission.

Contact the local political representative and ask for intervention with the regulatory authority to obtain
a decision regarding the submission.

Contact the company legal representative in order to begin legal proceedings to enforce the regulatory
authority’s response time.

NEW QUESTION 63
Why is it necessary to run supplemental safety pharmacology studies?

To substitute the utilization of GLP

To comply with regulatory authority requirements related to clinical studies

To evaluate potential adverse pharmacodynamics effects not addressed by the core battery

To provide adverse reaction reports and the results of the statistical data to the regulatory authority

NEW QUESTION 64
Company X encounters challenges in the global life cycle management of its medical devices. Which of
the following Is MOST appropriate for improving product life cycle management?

Utilize the STED template to complete global requirements.

Initiate a global submission process after all submission data are finalized.

Identify countries where special requirements exist during the product development phase.

Plan regulatory approval update meetings with senior management and stakeholders.

NEW QUESTION 65
An inspection of a manufacturing site determines that a number of manufacturing changes have been
implemented without obtaining the necessary regulatory clearance. Which of the following actions should
the regulatory affairs professional complete FIRST?

Stop product manufacturing.

Establish validation procedures.

Assess the impact of the changes.

Review the stability data for the changes.

NEW QUESTION 66
According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood
glucose self-testing kit?

Class A

Class B

Class C

Class D

NEW QUESTION 67
Which analysis method is MOST appropriate to prioritize risk and monitor the effectiveness of risk control
activities for a medical device?

Fishbone analysis

Failure modes, effects, and criticality analysis

Fault tree analysis

Quality by design analysis

NEW QUESTION 68
What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the
vendors comply with GMP requirements?

Ask the vendor to take responsibility.

Document and perform audits.

Request an inspection from a regulatory authority.

Request documentation from the sub-contractor.

NEW QUESTION 69
A company is developing a new line of products in an area that is new to the company. What is the BEST
approach?

Ask the trade association representative to provide an overview of the new product area to the
marketing team.

Obtain competitor research and provide the information to the management team.

Obtain regulatory documents and history and provide the information to R&D.

Summarize regulatory documents and history and provide the information to the management team.

NEW QUESTION 70
The safety database for an anti-hypertensive drug consists of the following:
. 461 patients exposed for three months
. 343 patients exposed for six months
. 112 patients exposed for nine months
. 74 patients exposed for 12 months
Overall exposure is 2.000 patients. Which long-term ICH data requirement has NOT been met?

100 patients for 12 months

200 patients for nine months

500 patients for three months

3.000 total patient exposures

NEW QUESTION 71
Which question is pertinent to demonstrate a new pharmaceutical’s effectiveness during evaluation by a
reimbursement agency?

“Is the product profitable for the manufacturer?”

“Is the product better than currently available alternatives?”

“Has the product been approved for mor&4nan 10 years?”

“Is the product an established gold standard?”

NEW QUESTION 72
Company X is planning to acquire the rights for a product marketed by Company Y. As part of due
diligence, what is the MOST important information the Company X regulatory affairs professional should
ask senior management to request from Company Y?

Intellectual properly

Clinical trial data

Safety issues

Marketing materials

NEW QUESTION 73
Who has the PRIMARY responsibility for recall of products with quality defects?

Consumer

Distributor

Manufacturer

Regulatory authority

NEW QUESTION 74
Which of the following is NOT required to be included in a marketing application?

Final printed label

Quality, safety, and efficacy Information

Administrative forms

Evidence of fee payment

NEW QUESTION 75
A company is considering the development of a medical device similar to those already available. Which
of the following should be evaluated FIRST when developing a clinical evaluation document?

Adverse event reports

Clinical experience

Clinical investigations

Literature search

NEW QUESTION 76
According to ICH, which of the following components of study information is NOT required in a clinical
study report?

Randomization scheme and codes

Protocol and protocol amendments

List of lECs or lRBs

Detailed CV of all investigators

NEW QUESTION 77
In preparation for the development of a new line of products, a regulatory affairs professional is asked to
prepare a short presentation for senior management. Which of the following topics is MOST important to
cover?

Potential clinical sites for the Phase III clinical trial

Regulatory requirements for labeling and packaging

Capacity of the manufacturing facilities to fully produce the new product

Previous actions taken by regulatory authorities on similar products

NEW QUESTION 78
A company is currently marketing an implantable orthopedic medical device. The R&D department is
planning to change the material used for the implant. The R&D department states that the change does
not impact the safety and effectiveness of the product. What action should the regulatory affairs
professional take FIRST?

No action is needed in this situation.

Prepare regulatory submissions that detail the medical device’s change in materials.

Review the content of change and supporting data for the equivalency with the current material.

Write a memo to file since the change does not impact product safety and effectiveness.

Loading …